284620 — Kainos Medicine Income Statement
0.000.00%
- KR₩35bn
- KR₩35bn
- KR₩267m
Annual income statement for Kainos Medicine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 1,662 | 130 | 267 |
Cost of Revenue | |||||
Gross Profit | — | 0 | 1,660 | 91 | 205 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 44.2 | 9,386 | 12,882 | 14,150 | 17,056 |
Operating Profit | -44.2 | -9,386 | -11,219 | -14,020 | -16,789 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 90.5 | -12,763 | -16,224 | -15,913 | -15,238 |
Provision for Income Taxes | |||||
Net Income After Taxes | 80.1 | -11,448 | -16,225 | -15,914 | -15,239 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 80.1 | -11,448 | -16,212 | -15,881 | -15,235 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 80.1 | -11,448 | -16,212 | -15,881 | -15,235 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 67.2 | -511 | -695 | -724 | -561 |
Dividends per Share |